JPRN-UMIN000004833已完成未知
Phase 2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer - Phase 2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancer
First Department of Surgery, Hamamatsu University School of Medicine0 个研究点目标入组 25 人开始时间: 2011年1月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active infectious disease 2) Patients with fever above 38 degrees. 3) Patients with severe complications. 4) Active concominant malignancies. 5) Patients with symptomatic brain metastasis. 6) Pleural effusion, pericardial effusion and ascites to need treatment 7) Patients with a history of hypersensitivity to the gemcitabine or nedaplation. 8) History of pregnancy or lactation. 9) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor.
研究者
相似试验
未知
1 期
Phase 1/2 study of the combination of gemcitabine and nedaplation for treatment of previously untreated advanced squamous cell lung cancerPreaviously untreated advanced advanced squamous cell lung cancerJPRN-C000000439Department of Respiratory Medicine of Kyoto University Hospital32
已完成
不适用
A combination phase I/II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancerpreviously untreated elderly non-small cell lung cancerJPRN-C000000072West Japan Oncology Group25
已完成
2 期
A combination phase II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer.on-small cell lung cancerJPRN-C000000135Institute of Biomedical Research and Innovation40
已完成
2 期
Phase II trial of the combination of gemcitabine and 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastomaNL-OMON39557Academisch Medisch Centrum16
进行中（未招募）
不适用
A phase II study of the combination of gemcitabine with 131I-MIBG therapy for children with neuroblastoma without other treatment options.relapsed or progressive neuroblastoma in pediatric patients of 1 to 18 yearsEUCTR2007-007974-45-NLAMC47